- Fourth-quarter revenue totaled $225.3 million, essentially flat year over year, while core revenue increased 4.3%, the strongest quarterly core growth of FY2026.
- Food Safety revenue rose 3.1%, with core growth of 5.8%, marking the segment’s best quarterly performance since the acquisition of 3M’s Food Safety business.
- Animal Safety revenue declined 8.2% year over year, although core growth was positive at 0.5% and sales improved 7% sequentially as supply constraints eased.
- Adjusted EBITDA increased to $45.4 million with a 20.2% margin, while adjusted EPS improved to $0.09.
- Neogen expects FY2027 revenue of $880-$885 million and adjusted EBITDA of $180-$182 million while advancing its Petrifilm manufacturing transition and planned genomics divestiture.
Neogen reported mixed fourth-quarter and full-year fiscal 2026 results, with accelerating momentum in Food Safety helping offset continued weakness in Animal Safety as the company advances strategic initiatives to improve long-term growth and profitability.
Food Safety leads growth
Food Safety revenue increased 3.1%, with core growth reaching 5.8%, the segment’s strongest quarterly performance since the 3M Food Safety acquisition. Growth was driven by indicator testing, culture media and bacterial sanitation products.
Animal Safety shows improvement
Animal Safety revenue declined 8.2% from the prior year, but sequential sales improved approximately 7% as supply constraints eased. Core growth returned to positive territory, and the company highlighted expanded support for New World screwworm response efforts through additional approved uses for Prozap insect control products.
Margins strengthen
Gross margin expanded to 47.8%, adjusted EBITDA reached $45.4 million and adjusted EPS increased to $0.09. Operating cash flow totaled $30.2 million and free cash flow reached $26.2 million during the quarter.
Looking ahead
Neogen remains on track to begin commercial Petrifilm manufacturing in Lansing later this year and continues pursuing the planned sale of its genomics business to Zoetis. The company expects fiscal 2027 revenue of $880-$885 million and adjusted EBITDA of $180-$182 million.
Read the full earnings report: https://neogen.com/investor-relations
Information sourced from the company’s earnings release.
